Welcome to our dedicated page for Qualigen Therapeutics SEC filings (Ticker: QLGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Qualigen Therapeutics, Inc. (historically NASDAQ: QLGN and now AIxCrypto Holdings, Inc. with symbol AIXC) provide detailed insight into the company’s transformation from a clinical-stage biotechnology issuer into a business that also emphasizes crypto, Web3, and decentralized AI activities. Through current reports on Form 8-K, registration statements on Form S-1, and proxy materials, investors can track how the company structures its financings, governs its operations, and discloses risks.
In its Form S-1 registration statement, the company outlines its current business mix: one early-clinical-stage program (QN-302), one preclinical Pan-RAS therapeutic program, and the C10 Cryptocurrency Asset Treasury with an 80% passive and 20% active allocation strategy to top cryptocurrencies. The S-1 also describes the terms of the Series B Convertible Preferred Stock, including conversion mechanics, voting rights, and the number of common shares that may be issued upon conversion, as well as the resale registration for those shares.
Multiple Form 8-K filings document the $41 million PIPE financing led by Faraday Future Intelligent Electric Inc., the Subscription Agreement and Registration Rights Agreement, and the Lead Investor Agreement that grants Faraday Future board nomination rights and participation rights in future financings. These filings also cover significant changes in senior management and the board of directors, the appointment and resignation of auditors, and Nasdaq correspondence regarding shareholder approval under Listing Rule 5635(b) and equity compliance under Listing Rule 5550(b)(1).
Additional filings, including the DEF 14A proxy statement, present the proposals submitted to stockholders, such as approval of the PIPE-related issuances and the 2025 Equity Incentive Plan. Name and ticker changes from Qualigen Therapeutics, Inc. (QLGN) to AIxCrypto Holdings, Inc. (AIXC) are recorded through amendments to the certificate of incorporation and related 8-K disclosures.
On Stock Titan’s filings page, users can review these documents as they are made available through EDGAR and use AI-powered summaries to understand complex items like preferred stock designations, treasury policies, and Nasdaq compliance matters. The page also surfaces key forms such as 10-Q and 10-K when filed, along with any future Form 4 insider transaction reports, to help readers analyze capital structure, governance developments, and the evolution of the company’s dual focus on therapeutics and AI × Web3 initiatives.
Qualigen Therapeutics reports several governance and audit changes. Its prior auditor, WithumSmith+Brown, resigned effective October 1, 2025, ending engagements for the September 30, 2025 quarterly review and the December 31, 2025 year-end audit. Withum’s report on the year ended December 31, 2024 included an explanatory paragraph about substantial doubt regarding the company’s ability to continue as a going concern, but otherwise was not adverse or qualified, and the company states there were no disagreements or other reportable events beyond previously disclosed material weaknesses in internal control over financial reporting.
The Audit Committee approved Macias Gini & O’Connell LLP as new independent auditor for the 2025 year-end audit and specified interim reviews through September 30, 2026, subject to client acceptance procedures. Effective October 2, 2025, the company appointed Jiawei Wang as Co‑Chief Executive Officer and Koti Meka as Chief Financial Officer, and added three new directors, who also joined key board committees. Three existing directors resigned in connection with a recent private placement, with the company stating these departures were not due to disagreements.
Qualigen Therapeutics (QLGN) closed a $41,000,000 private placement on September 29, 2025, selling 337,432 shares of common stock at $2.246 and 17,783 shares of Series B Convertible Preferred Stock at a $1,000 stated value. The Series B converts into common at a $2.246 conversion price after Stockholder Approval under Nasdaq Rule 5635, with allocations capped at 19.99% ownership per investor at closing.
The company plans to use up to
Qualigen Therapeutics, Inc. reported that its Board of Directors appointed Kevin Chen as an independent director, effective September 26, 2025. As of this appointment, he has not yet been assigned to any Board committees. Chen is currently Chief Economist and CIO of Horizon Financial and serves on several public company boards, including CurrenC Group, Australian Oilseeds Investments, Scage Future and Capitan Investment Ltd. His background includes senior investment roles at Credit Agricole/Amundi Asset Management and Morgan Stanley, as well as academic positions at New York University and other institutions.
Qualigen Therapeutics entered into a private placement on September 19, 2025, under which investors, led by Faraday Future Intelligent Electric Inc., agreed to purchase
Univest Securities will receive a 5.5% cash fee on gross proceeds, warrants equal to 6% of securities sold exercisable at
Qualigen Therapeutics, Inc. filed an S-1 registration statement seeking to offer additional common stock under the Nasdaq Capital Market ticker QLGN. The document lists a post-offering common share count of 4,909,932 shares assuming all offered shares are sold and shows existing selling stockholders controlling a combined 3,214,292 shares.
The filing discloses recent financing activity: issuance of 32,092 shares to Alpha in lieu of redemption payments at a weighted average price of
Qualigen Therapeutics, Inc. filed a current report describing an amendment to its secured borrowing arrangement with Marizyme, Inc. On September 15, 2025, the company entered into Amendment No. 1 to its Amended and Restated Secured Demand Promissory Note dated August 21, 2025.
The amendment corrects the note’s maturity date to August 21, 2026, increases the advance and principal amount by $75,000, and results in a revised outstanding principal balance of $4,526,462.18. The additional advance accrues interest at the same rate set in the existing note, and the company’s obligations remain secured under the existing Security Agreement. The amendment also triggers disclosure of a direct financial obligation under the relevant reporting item.
Qualigen Therapeutics reported that a Nasdaq Hearings Panel has issued a decision on its continued listing. The company previously received an exception to meet Nasdaq’s stockholders’ equity requirement of $2.5 million by July 28, 2025, but its June 30, 2025 Form 10-Q showed stockholders’ equity of approximately negative $1.6 million, so it did not meet the deadline.
The company subsequently closed a private placement of Series A-3 Preferred Stock with net proceeds of about $4.3 million and amended a promissory note with Marizyme, Inc., which increased stockholders’ equity by more than $600,000. The Panel stated that these actions cannot be used to show compliance as of July 28 but granted a final exception to demonstrate compliance in the Form 10-Q for the quarter ending September 30, 2025, which must be filed no later than November 15, 2025. If compliance is not demonstrated then, no additional time will be granted. The company has regained compliance with Nasdaq’s periodic filing rule.
Qualigen Therapeutics has expanded and restructured its lending arrangement with Marizyme through an Amended and Restated Secured Demand Promissory Note with a principal balance of $4,451,462.18. The note carries 18% annual interest, with all principal and interest due in a single balloon payment on August 21, 2026, and the rate rising by 5% upon default.
Qualigen agreed to conditionally forbear from demanding payment for 365 days unless Marizyme defaults, and obtained a security interest in substantially all of Marizyme’s assets. The company also highlights a recent private placement of 4,500 shares of Series A-3 Preferred Stock for approximately $4.5 million in gross proceeds, resulting in net proceeds of $4,257,937.50, and states it believes total shareholders’ equity now exceeds $2.5 million.